US Patent

US12194030 — Treatment of migraine

Method of Use · Assigned to Allergan Pharmaceuticals International Ltd · Expires 2041-12-22 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating migraine with or without aura using ubrogepant, including in patients with certain health conditions or taking specific medications.

USPTO Abstract

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

Drugs covered by this patent

Ubrelvy (UBROGEPANT) · AbbVie

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4121`	—	Ubrelvy

Patent Metadata

Patent number: US12194030
Jurisdiction: US
Classification: Method of Use
Expires: 2041-12-22
Drug substance claim: No
Drug product claim: No
Assignee: Allergan Pharmaceuticals International Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.